Newly Discovered Drug Is Able To Inhibit Neurotoxic Tau Oligomers In Brains, Paving The Way For A Potential Cure for Alzheimer

Oligomerix and Feinstein Institutes Publish In Vivo Alzheimer’s Disease Treatment Data

Oligomerix Awarded $2.18 Million SBIR Grant for Tau Oligomer Inhibitor for Alzheimer’s Disease and Related Disorders

Oligomerix Receives Ongoing Support from NIH and Moves Forward with IND-enabling Studies

Oligomerix to Participate in the NIH Innovation Zone at 2019 BIO International Convention

Oligomerix Awarded 1.98 Million NIH SBIR-Phase IIb Grant

Oligomerix Relocates to Albert Einstein College of Medicine Campus

Oligomerix Inc. Awarded 2.49 Million Fast-Track

Oligomerix, Inc. Awarded National Institute on Aging SBIR Grant for Development of Alzheimer’s Disease Specific Biomarker

Oligomerix Awarded a Grant for its Alzheimer’s Drug Discovery Program Targeting Tau Oligomers from the National Institutes of Health